Skip to main content
SpringerLink
Log in

Barrett’s Esophagus: Diagnosis and Management

  • Chapter
  • First Online:
Esophageal Cancer

  • 1085 Accesses

Abstract

Barrett’s esophagus (BE) is a premalignant lesion in the esophagus that carries a risk of transforming into esophageal adenocarcinoma (EAC). It is believed that virtually all EACs arise from BE. The incidence of BE appears to have increased over the last four decades for unclear reasons. Risk factors for BE include chronic gastroesophageal reflux, old age, male gender, obesity, and tobacco use; the majority of BE cases occur in males and approximately 1–5% of the population is affected. Individuals with BE are monitored on a regular basis with endoscopic and esophageal biopsies to assess for evidence of histologic progression defined by the presence of dysplasia. Those individuals with high-grade dysplasia and early EAC are now treated with endoscopic procedures, including endomucosal resection and radiofrequency ablation. Advances are being made in the area of BE and EAC molecular markers to improve the ability to diagnose and manage BE and EAC as well as in potential chemoprevention therapies. The current management and evolving areas with regards to the prevention, detection, monitoring, and management of BE will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Paulson TG, Reid BJ. Focus on Barrett’s esophagus and esophageal adenocarcinoma. Cancer Cell. 2004;6(1):11–6. https://doi.org/10.1016/j.ccr.2004.06.021.

    Article  CAS  PubMed  Google Scholar 

  2. Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett’s esophagus. Biomark Med. 2011;5(3):397–404. https://doi.org/10.2217/bmm.11.40.

    Article  PubMed  Google Scholar 

  3. Verbeek RE, Leenders M, Ten Kate FJ, van Hillegersberg R, Vleggaar FP, van Baal JW, van Oijen MG, Siersema PD. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109(8):1215–22. https://doi.org/10.1038/ajg.2014.156.

    Article  PubMed  Google Scholar 

  4. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23(12):3155–62. https://doi.org/10.1093/annonc/mds181.

    Article  CAS  PubMed  Google Scholar 

  5. Barrett NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg. 1950;38(150):175–82.

    Article  CAS  PubMed  Google Scholar 

  6. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627–36. https://doi.org/10.1001/jama.2013.226450.

    Article  CAS  PubMed  Google Scholar 

  7. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87–101. https://doi.org/10.1038/nrc2773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–57. https://doi.org/10.1093/jnci/djr203.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dulai GS, Shekelle PG, Jensen DM, Spiegel BM, Chen J, Oh D, Kahn KL. Dysplasia and risk of further neoplastic progression in a regional veterans administration Barrett’s cohort. Am J Gastroenterol. 2005;100(4):775–83.

    Article  PubMed  Google Scholar 

  10. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. ClinGastroenterolHepatol. 2006;4(5):566–72.

    Google Scholar 

  11. Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, McMenamin U, Bannon F, Hicks B, Kennedy G, Gavin AT, Murray LJ. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut 2015;64:20–25. https://doi.org/10.1136/gutjnl-2013-305506.

    Article  PubMed  Google Scholar 

  12. Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A, Sharma P. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol. 2012;107(11):1655–61. https://doi.org/10.1038/ajg.2012.299.

    Article  PubMed  Google Scholar 

  13. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344(8936):1533–6.

    Article  CAS  PubMed  Google Scholar 

  14. Connor MJ, Weston AP, Mayo MS, Sharma P. The prevalence of Barrett’s esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population. Dig Dis Sci. 2004;49(6):920–4.

    Article  PubMed  Google Scholar 

  15. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, Dunne D, Rahmani EY, Helper DJ. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125(6):1670–7.

    Article  PubMed  Google Scholar 

  16. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF Jr, Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM. Prediction of Barrett’s esophagus among men. Am J Gastroenterol. 2013;108(3):353–62. https://doi.org/10.1038/ajg.2012.446.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agreus L. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–31. https://doi.org/10.1053/j.gastro.2005.08.053.

    Article  PubMed  Google Scholar 

  18. Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, Farahmand BY, Winchester CC, Roda E, Bazzoli F. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–9. https://doi.org/10.1136/gut.2007.145177.

    Article  CAS  PubMed  Google Scholar 

  19. Ronkainen J, Talley NJ, Storskrubb T, Johansson SE, Lind T, Vieth M, Agreus L, Aro P. Erosive esophagitis is a risk factor for Barrett’s esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol. 2011;106(11):1946–52. https://doi.org/10.1038/ajg.2011.326.

    Article  PubMed  Google Scholar 

  20. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus. Am J Gastroenterol. 2010;105(8):1729., 1730–1727; quiz 1738. https://doi.org/10.1038/ajg.2010.194.

    Article  PubMed  Google Scholar 

  21. American Gastroenterological A, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91. https://doi.org/10.1053/j.gastro.2011.01.030.

    Article  Google Scholar 

  22. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O’Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J, British Society of G. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42. https://doi.org/10.1136/gutjnl-2013-305372.

    Article  PubMed  Google Scholar 

  23. Spechler SJ, Souza RF. Barrett’s Esophagus. N Engl J Med. 2014;371(9):836–45. https://doi.org/10.1056/NEJMra1314704.

    Article  CAS  PubMed  Google Scholar 

  24. de Jonge PJ, van Blankenstein M, Grady WM, Kuipers EJ. Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut. 2014;63(1):191–202. https://doi.org/10.1136/gutjnl-2013-305490.

    Article  PubMed  Google Scholar 

  25. Rubenstein JH. Risk factors for Barrett’s esophagus. Curr Opin Gastroenterol. 2014;30(4):408–14. https://doi.org/10.1097/MOG.0000000000000084.

    Article  PubMed  Google Scholar 

  26. Leggett CL, Gorospe EC, Calvin AD, Harmsen WS, Zinsmeister AR, Caples S, Somers VK, Dunagan K, Lutzke L, Wang KK, Iyer PG. Obstructive sleep apnea is a risk factor for Barrett’s esophagus. ClinGastroenterolHepatol. 2014;12(4):583–588.e581. https://doi.org/10.1016/j.cgh.2013.08.043.

    Article  Google Scholar 

  27. Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, Reynolds JV, Murray LJ. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol: WJG. 2007;13(10):1585–94.

    Article  PubMed  Google Scholar 

  28. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut. 2008;57(6):727–33. doi:gut.2007.132068 [pii]

    Article  CAS  PubMed  Google Scholar 

  29. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83. https://doi.org/10.1056/NEJMoa1103042.

    Article  CAS  PubMed  Google Scholar 

  30. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030–6. https://doi.org/10.1136/gut.2009.176701.

    Article  PubMed  Google Scholar 

  31. Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30. https://doi.org/10.1038/ajg.2010.171.

    Article  PubMed  Google Scholar 

  32. Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, Gupta N, Gaddam S, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Goldblum J, Lieberman DA, Sampliner RE, Sharma P. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141(4):1179–86,. 1186.e1171. https://doi.org/10.1053/j.gastro.2011.06.055.

    Article  PubMed  Google Scholar 

  33. Thota PN, Lee HJ, Goldblum JR, Liu X, Sanaka MR, Gohel T, Kanadiya M, Lopez R. Risk stratification of patients with Barrett’s esophagus and low-grade dysplasia or indefinite for dysplasia. ClinGastroenterolHepatol. 2015;13(3):459–65.e1. https://doi.org/10.1016/j.cgh.2014.07.049.

    Article  PubMed  Google Scholar 

  34. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394–8.

    Article  PubMed  Google Scholar 

  35. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O’Connell S, Seidel UJ, Sonnenberg A. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120(7):1607–19.

    Article  CAS  PubMed  Google Scholar 

  36. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630–9.

    Article  CAS  PubMed  Google Scholar 

  37. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95(8):1888–93.

    Article  CAS  PubMed  Google Scholar 

  38. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96(11):3071–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, Gammon MD, Risch HA, Casson AG, Freedman ND, Chow WH, Wu AH, Bernstein L, Nyren O, Pandeya N, Whiteman DC, Vaughan TL. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal adenocarcinoma consortium (BEACON). PLoS One. 2014;9(7):e103508. https://doi.org/10.1371/journal.pone.0103508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Gaddam S, Singh M, Balasubramanian G, Thota P, Gupta N, Wani S, Higbee AD, Mathur SC, Horwhat JD, Rastogi A, Young PE, Cash BD, Bansal A, Vargo JJ, Falk GW, Lieberman DA, Sampliner RE, Sharma P. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013;145(3):548–553.e541. https://doi.org/10.1053/j.gastro.2013.05.040.

    Article  PubMed  Google Scholar 

  41. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–88. https://doi.org/10.1056/NEJMoa0808145.

    Article  CAS  PubMed  Google Scholar 

  42. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102(4 Pt 1):1212–9.

    Article  CAS  PubMed  Google Scholar 

  43. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comparison with traditional long segment Barrett’s esophagus. Am J Gastroenterol. 1997;92(3):407–13.

    CAS  PubMed  Google Scholar 

  44. Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda-Pedraza E, Lee HJ, Hirota WK, Wong RK. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol. 2007;102(3):497–506.

    Article  PubMed  Google Scholar 

  45. Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238(4):458–64;. discussion 464-456. https://doi.org/10.1097/01.sla.0000090443.97693.c3.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Committee ASoP, Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, Chathadi KV, Decker GA, Fanelli RD, Fisher DA, Foley KQ, Hwang JH, Jain R, Jue TL, Khan KM, Lightdale J, Malpas PM, Maple JT, Pasha SF, Saltzman JR, Sharaf RN, Shergill A, Dominitz JA, Cash BD. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76(6):1087–94. https://doi.org/10.1016/j.gie.2012.08.004.

    Article  Google Scholar 

  47. Takubo K, Vieth M, Aida J, Sawabe M, Kumagai Y, Hoshihara Y, Arai T. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion. 2009;80(4):248–57. https://doi.org/10.1159/000235923.

    Article  PubMed  Google Scholar 

  48. Kusano C, Kaltenbach T, Shimazu T, Soetikno R, Gotoda T. Can Western endoscopists identify the end of the lower esophageal palisade vessels as a landmark of esophagogastric junction? J Gastroenterol. 2009;44(8):842–6. https://doi.org/10.1007/s00535-009-0083-1.

    Article  PubMed  Google Scholar 

  49. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N Engl J Med. 1976;295(9):476–80. https://doi.org/10.1056/NEJM197608262950904.

    Article  CAS  PubMed  Google Scholar 

  50. Westerhoff M, Hovan L, Lee C, Hart J. Effects of dropping the requirement for goblet cells from the diagnosis of Barrett’s esophagus. ClinGastroenterolHepatol. 2012;10(11):1232–6. https://doi.org/10.1016/j.cgh.2012.05.013.

    Article  Google Scholar 

  51. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? DisEsophagus. 2007;20(1):36–41.

    CAS  Google Scholar 

  52. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett’s esophagus: a review of the literature. J Gastrointest Surg. 2011;15(5):708–18. https://doi.org/10.1007/s11605-011-1485-y.

    Article  PubMed  Google Scholar 

  53. Varghese S, Lao-Sirieix P, Fitzgerald RC. Identification and clinical implementation of biomarkers for Barrett’s esophagus. Gastroenterology. 2012;142(3):435–441.e432. https://doi.org/10.1053/j.gastro.2012.01.013.

    Article  PubMed  Google Scholar 

  54. Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett’s esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013;144(7):1375–83,. 1383.e1371. https://doi.org/10.1053/j.gastro.2013.02.050.

    Article  PubMed  Google Scholar 

  55. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4(2):e67. doi:06-PLME-RA-0387R2 [pii]

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, Johnston BT, Arthur K, McManus DT, Novelli MR, O’Donovan M, Cardwell CR, Lovat LB, Murray LJ, Fitzgerald RC. Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology. 2012;143(4):927–35e923. https://doi.org/10.1053/j.gastro.2012.06.041.

    Article  CAS  PubMed  Google Scholar 

  57. Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett’s esophagus. Cancer Epidemiol Biomark Prev. 2008;17(6):1380–5. https://doi.org/10.1158/1055-9965.EPI-07-2734.

    Article  CAS  Google Scholar 

  58. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38(4):468–73.

    Article  CAS  PubMed  Google Scholar 

  59. Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193–9. https://doi.org/10.1016/j.canlet.2012.02.036.

    Article  CAS  PubMed  Google Scholar 

  60. Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martinez C, Munitiz V, de Angulo DR, Bermejo J, Molina J, Cayuela ML, Yelamos J. Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg. 2013;257(5):886–93. https://doi.org/10.1097/SLA.0b013e31826ddba6.

    Article  PubMed  Google Scholar 

  61. Alvarez Herrero L, Curvers WL, van Vilsteren FG, Wolfsen H, Ragunath K, Wong Kee Song LM, Mallant-Hent RC, van Oijen A, Scholten P, Schoon EJ, Schenk EB, Weusten BL, Bergman JG. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45(11):876–82. https://doi.org/10.1055/s-0033-1344952.

    Article  PubMed  Google Scholar 

  62. Vahabzadeh B, Seetharam AB, Cook MB, Wani S, Rastogi A, Bansal A, Early DS, Sharma P. Validation of the Prague C & M criteria for the endoscopic grading of Barrett’s esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc. 2012;75(2):236–41. https://doi.org/10.1016/j.gie.2011.09.017.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Montgomery E, Bronner MP, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Goldblum JR. Are ulcers a marker for invasive carcinoma in Barrett’s esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol. 2002;97(1):27–31. https://doi.org/10.1111/j.1572-0241.2002.05420.x.

    Article  PubMed  Google Scholar 

  64. Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, ten Kate FJ, Fockens P, Bergman JJ. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929–36. https://doi.org/10.1055/s-2005-870433.

    Article  CAS  PubMed  Google Scholar 

  65. Thomas T, Gilbert D, Kaye PV, Penman I, Aithal GP, Ragunath K. High-resolution endoscopy and endoscopic ultrasound for evaluation of early neoplasia in Barrett’s esophagus. Surg Endosc. 2010;24(5):1110–6. https://doi.org/10.1007/s00464-009-0737-3.

    Article  CAS  PubMed  Google Scholar 

  66. Pech O, Gossner L, Manner H, May A, Rabenstein T, Behrens A, Berres M, Huijsmans J, Vieth M, Stolte M, Ell C. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy. 2007;39(7):588–93. https://doi.org/10.1055/s-2007-966363.

    Article  CAS  PubMed  Google Scholar 

  67. Moss A, Bourke MJ, Hourigan LF, Gupta S, Williams SJ, Tran K, Swan MP, Hopper AD, Kwan V, Bailey AA. Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol. 2010;105(6):1276–83. https://doi.org/10.1038/ajg.2010.1.

    Article  PubMed  Google Scholar 

  68. Mino-Kenudson M, Hull MJ, Brown I, Muzikansky A, Srivastava A, Glickman J, Park DY, Zuckerberg L, Misdraji J, Odze RD, Lauwers GY. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007;66(4):660–6. quiz 767, 769doi:S0016-5107(07)00405-1[pii]

    Article  PubMed  Google Scholar 

  69. Mino-Kenudson M, Brugge WR, Puricelli WP, Nakatsuka LN, Nishioka NS, Zukerberg LR, Misdraji J, Lauwers GY. Management of superficial Barrett’s epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27 cases. Am J Surg Pathol. 2005;29(5):680–6. doi:00000478-200505000-00016[pii]

    Article  PubMed  Google Scholar 

  70. Mandal RV, Forcione DG, Brugge WR, Nishioka NS, Mino-Kenudson M, Lauwers GY. Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am J Surg Pathol. 2009;33(4):620–5. https://doi.org/10.1097/PAS.0b013e31818d632f.

    Article  PubMed  Google Scholar 

  71. Wani S, Abrams J, Edmundowicz SA, Gaddam S, Hovis CE, Green D, Gupta N, Higbee A, Bansal A, Rastogi A, Early D, Lightdale CJ, Sharma P. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett’s esophagus patients with visible and flat neoplasia: a multicenter cohort study. Dig Dis Sci. 2013;58(6):1703–9. https://doi.org/10.1007/s10620-013-2689-7.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47(2):251–5. https://doi.org/10.1136/gut.47.2.251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95(12):3383–7.

    Article  CAS  PubMed  Google Scholar 

  74. Lim CH, Treanor D, Dixon MF, Axon AT. Low-grade dysplasia in Barrett’s esophagus has a high risk of progression. Endoscopy. 2007;39(7):581–7. https://doi.org/10.1055/s-2007-966592.

    Article  CAS  PubMed  Google Scholar 

  75. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32(4):368–78.

    Article  CAS  PubMed  Google Scholar 

  76. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54(18):4855–78.

    CAS  PubMed  Google Scholar 

  77. Kaye PV, Haider SA, Ilyas M, James PD, Soomro I, Faisal W, Catton J, Parsons SL, Ragunath K. Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology. 2009;54(6):699–712. https://doi.org/10.1111/j.1365-2559.2009.03288.x.

    Article  PubMed  Google Scholar 

  78. Skacel M, Petras RE, Rybicki LA, Gramlich TL, Richter JE, Falk GW, Goldblum JR. p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol. 2002;97(10):2508–13. https://doi.org/10.1111/j.1572-0241.2002.06032.x.

    Article  CAS  PubMed  Google Scholar 

  79. Kaye PV, Haider SA, James PD, Soomro I, Catton J, Parsons SL, Ragunath K, Ilyas M. Novel staining pattern of p53 in Barrett’s dysplasia – the absent pattern. Histopathology. 2010;57(6):933–5. https://doi.org/10.1111/j.1365-2559.2010.03715.x.

    Article  PubMed  Google Scholar 

  80. Khan S, Do KA, Kuhnert P, Pillay SP, Papadimos D, Conrad R, Jass JR. Diagnostic value of p53 immunohistochemistry in Barrett’s esophagus: an endoscopic study. Pathology. 1998;30(2):136–40.

    Article  CAS  PubMed  Google Scholar 

  81. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, Forman D, Wild CP. TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55(10):1390–7. https://doi.org/10.1136/gut.2005.083295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP. Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000;92(16):1316–21.

    Article  CAS  PubMed  Google Scholar 

  83. Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673–80. https://doi.org/10.1038/ajg.2009.437.

    Article  CAS  PubMed  Google Scholar 

  84. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50.; quiz 51. https://doi.org/10.1038/ajg.2015.322.

    Article  CAS  PubMed  Google Scholar 

  85. Sturm MB, Wang TD. Emerging optical methods for surveillance of Barrett’s oesophagus. Gut. 2015;64(11):1816–23. https://doi.org/10.1136/gutjnl-2013-306706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Coletta M, Sami SS, Nachiappan A, Fraquelli M, Casazza G, Ragunath K. Acetic acid chromoendoscopy for the diagnosis of early neoplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc. 2016;83(1):57–67e51. https://doi.org/10.1016/j.gie.2015.07.023.

    Article  PubMed  Google Scholar 

  87. Sharma P, Hawes RH, Bansal A, Gupta N, Curvers W, Rastogi A, Singh M, Hall M, Mathur SC, Wani SB, Hoffman B, Gaddam S, Fockens P, Bergman JJ. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut. 2013;62(1):15–21. https://doi.org/10.1136/gutjnl-2011-300962.

    Article  PubMed  Google Scholar 

  88. Qumseya BJ, Wang H, Badie N, Uzomba RN, Parasa S, White DL, Wolfsen H, Sharma P, Wallace MB. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2013;11(12):1562–70e1561-1562. https://doi.org/10.1016/j.cgh.2013.06.017.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Boerwinkel DF, Holz JA, Aalders MC, Visser M, Meijer SL, Van Berge Henegouwen MI, Weusten BL, Bergman JJ. Third-generation autofluorescence endoscopy for the detection of early neoplasia in Barrett’s esophagus: a pilot study. Dis Esophagus. 2014;27(3):276–84. https://doi.org/10.1111/dote.12094.

    Article  CAS  PubMed  Google Scholar 

  90. Boerwinkel DF, Holz JA, Kara MA, Meijer SL, Wallace MB, Wong Kee Song LM, Ragunath K, Wolfsen HC, Iyer PG, Wang KK, Weusten BL, Aalders MC, Curvers WL, Bergman JJ. Effects of autofluorescence imaging on detection and treatment of early neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12(5):774–81. https://doi.org/10.1016/j.cgh.2013.10.013.

    Article  PubMed  Google Scholar 

  91. Curvers WL, Alvarez Herrero L, Wallace MB, Wong Kee Song LM, Ragunath K, Wolfsen HC, Prasad GA, Wang KK, Subramanian V, Weusten BL, Ten Kate FJ, Bergman JJ. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus. Gastroenterology. 2010;139(4):1106–14. https://doi.org/10.1053/j.gastro.2010.06.045.

    Article  PubMed  Google Scholar 

  92. Curvers WL, van Vilsteren FG, Baak LC, Bohmer C, Mallant-Hent RC, Naber AH, van Oijen A, Ponsioen CY, Scholten P, Schenk E, Schoon E, Seldenrijk CA, Meijer GA, ten Kate FJ, Bergman JJ. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett’s neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc. 2011;73(2):195–203. https://doi.org/10.1016/j.gie.2010.10.014.

    Article  PubMed  Google Scholar 

  93. Li M, Anastassiades CP, Joshi B, Komarck CM, Piraka C, Elmunzer BJ, Turgeon DK, Johnson TD, Appelman H, Beer DG, Wang TD. Affinity peptide for targeted detection of dysplasia in Barrett’s esophagus. Gastroenterology. 2010;139(5):1472–80. https://doi.org/10.1053/j.gastro.2010.07.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, O’Donovan M, Novelli M, Lovat LB, Eng WS, Mahal LK, Brindle KM, Fitzgerald RC. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett’s esophagus. Nat Med. 2012;18(2):315–21. https://doi.org/10.1038/nm.2616.

    Article  CAS  PubMed  Google Scholar 

  95. Sturm MB, Joshi BP, Lu S, Piraka C, Khondee S, Elmunzer BJ, Kwon RS, Beer DG, Appelman HD, Turgeon DK, Wang TD. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med. 2013;5(184):184ra161. https://doi.org/10.1126/scitranslmed.3004733.

    Article  CAS  Google Scholar 

  96. Neves AA, Di Pietro M, O’Donovan M, Waterhouse DJ, Bohndiek SE, Brindle KM, Fitzgerald RC. Detection of early neoplasia in Barrett’s esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue. Endoscopy. 2018;50(6):618–25. https://doi.org/10.1055/s-0043-124080.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Kohli DR, Schubert ML, Zfass AM, Shah TU. Performance characteristics of optical coherence tomography in assessment of Barrett’s esophagus and esophageal cancer: systematic review. Dis Esophagus. 2017;30(11):1–8. https://doi.org/10.1093/dote/dox049.

    Article  CAS  PubMed  Google Scholar 

  98. Wolfsen HC, Sharma P, Wallace MB, Leggett C, Tearney G, Wang KK. Safety and feasibility of volumetric laser endomicroscopy in patients with Barrett’s esophagus (with videos). Gastrointest Endosc. 2015;82(4):631–40. https://doi.org/10.1016/j.gie.2015.03.1968.

    Article  PubMed  Google Scholar 

  99. Alshelleh M, Inamdar S, McKinley M, Stewart M, Novak JS, Greenberg RE, Sultan K, Devito B, Cheung M, Cerulli MA, Miller LS, Sejpal DV, Vegesna AK, Trindade AJ. Incremental yield of dysplasia detection in Barrett’s esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc. 2018;88(1):35–42. https://doi.org/10.1016/j.gie.2018.01.032.

    Article  PubMed  Google Scholar 

  100. Leggett CL, Gorospe EC, Chan DK, Muppa P, Owens V, Smyrk TC, Anderson M, Lutzke LS, Tearney G, Wang KK. Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrett’s esophagus. Gastrointest Endosc. 2016;83(5):880–888.e2. https://doi.org/10.1016/j.gie.2015.08.050.

    Article  PubMed  Google Scholar 

  101. Xiong YQ, Ma SJ, Zhou JH, Zhong XS, Chen Q. A meta-analysis of confocal laser endomicroscopy for the detection of neoplasia in patients with Barrett’s esophagus. J Gastroenterol Hepatol. 2016;31(6):1102–10. https://doi.org/10.1111/jgh.13267.

    Article  PubMed  Google Scholar 

  102. Peery AF, Hoppo T, Garman KS, Dellon ES, Daugherty N, Bream S, Sanz AF, Davison J, Spacek M, Connors D, Faulx AL, Chak A, Luketich JD, Shaheen NJ, Jobe BA, Barrett’s Esophagus Risk C. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75(5):945–53e942. https://doi.org/10.1016/j.gie.2012.01.021.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Shariff MK, Varghese S, O’Donovan M, Abdullahi Z, Liu X, Fitzgerald RC, di Pietro M. Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett’s esophagus. Endoscopy. 2016;48(2):110–6. https://doi.org/10.1055/s-0034-1393310.

    Article  PubMed  Google Scholar 

  104. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, Sami SS, Kaye P, Novelli M, Disep B, Ostler R, Aigret B, North BV, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Sasieni PD, Fitzgerald RC, Group BS. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;12(1):e1001780. https://doi.org/10.1371/journal.pmed.1001780.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C. Cost effectiveness of screening patients with gastroesophageal reflux disease for Barrett’s esophagus with a minimally invasive cell sampling device. Clin Gastroenterol Hepatol. 2017;15(9):1397–404e1397. https://doi.org/10.1016/j.cgh.2017.02.017.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, Fessas P, Walker E, Varghese S, Evan T, Lao-Sirieix PS, O’Donovan M, Malhotra S, Novelli M, Disep B, Kaye PV, Lovat LB, Haidry R, Griffin M, Ragunath K, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Ostler R, Aigret B, Sasieni PD, Fitzgerald RC, group Bs. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(1):23–31. https://doi.org/10.1016/S2468-1253(16)30118-2.

    Article  PubMed  Google Scholar 

  107. Chettouh H, Mowforth O, Galeano-Dalmau N, Bezawada N, Ross-Innes C, MacRae S, Debiram-Beecham I, O’Donovan M, Fitzgerald RC. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67(11):1942–9. https://doi.org/10.1136/gutjnl-2017-314026.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz CO, Guda K, Barnholtz-Sloan JS, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Thota PN, Willis JE, Chak A, Markowitz SD. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med. 2018;10(424):eaao5848. https://doi.org/10.1126/scitranslmed.aao5848.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Matsuzaki J, Suzuki H. Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma. BMJ Open Gastroenterol. 2017;4(1):e000160. https://doi.org/10.1136/bmjgast-2017-000160.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Buas MF, Gu H, Djukovic D, Zhu J, Onstad L, Reid BJ, Raftery D, Vaughan TL. Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017;13(3):23. https://doi.org/10.1007/s11306-016-1154-y.

  111. Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D, Thompson A. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012;106(5):955–61. https://doi.org/10.1038/bjc.2012.15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Chiam K, Wang T, Watson DI, Mayne GC, Irvine TS, Bright T, Smith L, White IA, Bowen JM, Keefe D, Thompson SK, Jones ME, Hussey DJ. Circulating serum Exosomal miRNAs as potential biomarkers for Esophageal adenocarcinoma. J Gastrointest Surg. 2015;19(7):1208–15. https://doi.org/10.1007/s11605-015-2829-9.

    Article  PubMed  Google Scholar 

  113. Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol. 2014;110(5):599–610. https://doi.org/10.1002/jso.23759.

    Article  PubMed  Google Scholar 

  114. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett’s oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20(6):637–43. https://doi.org/10.1111/j.1365-2036.2004.02127.x.

    Article  CAS  PubMed  Google Scholar 

  115. Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, Bruno MJ, ProBar Study G. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382–8. https://doi.org/10.1016/j.cgh.2012.11.014.

    Article  CAS  PubMed  Google Scholar 

  116. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39(9):984–91. https://doi.org/10.1111/apt.12693.

    Article  CAS  PubMed  Google Scholar 

  117. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett’s esophagus with and without dysplasia. Dis Esophagus. 2007;20(6):516–22.

    Article  CAS  PubMed  Google Scholar 

  118. Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci. 2012;57(10):2625–32. https://doi.org/10.1007/s10620-012-2313-2.

    Article  CAS  PubMed  Google Scholar 

  119. Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108(3):386–91. https://doi.org/10.1038/ajg.2012.440.

    Article  PubMed  Google Scholar 

  120. Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ, Probar-study G. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology. 2011;141(6):2000–8;. quiz e2013-2004. https://doi.org/10.1053/j.gastro.2011.08.036.

    Article  CAS  PubMed  Google Scholar 

  121. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138(7):2260–6. https://doi.org/10.1053/j.gastro.2010.02.045.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6(12):945–52.

    Article  CAS  PubMed  Google Scholar 

  123. Khalaf N, Nguyen T, Ramsey D, El-Serag HB. Nonsteroidal anti-inflammatory drugs and the Risk of Barrett’s Esophagus. Clin Gastroenterol Hepatol. 2014;12(11):1832–9.e6. https://doi.org/10.1016/j.cgh.2014.04.027.

    Article  PubMed Central  CAS  Google Scholar 

  124. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285(18):2331–8.

    Article  CAS  PubMed  Google Scholar 

  125. Tran T, Spechler SJ, Richardson P, El-Serag HB. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a veterans affairs cohort study. Am J Gastroenterol. 2005;100(5):1002–8.

    Article  PubMed  Google Scholar 

  126. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review. Am J Gastroenterol. 2012;107(6):850–62. quiz 863. https://doi.org/10.1038/ajg.2012.78.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Yang D, Zou F, Xiong S, Forde JJ, Wang Y, Draganov PV. Endoscopic submucosal dissection for early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc. 2018;87(6):1383–93. https://doi.org/10.1016/j.gie.2017.09.038.

    Article  PubMed  Google Scholar 

  128. Konda VJ, Gonzalez Haba Ruiz M, Koons A, Hart J, Xiao SY, Siddiqui UD, Ferguson MK, Posner M, Patti MG, Waxman I. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated Neoplasia. Clin Gastroenterol Hepatol. 2014;12(12):2002–10.e1–2. https://doi.org/10.1016/j.cgh.2014.04.010.

    Article  Google Scholar 

  129. Chung A, Bourke MJ, Hourigan LF, Lim G, Moss A, Williams SJ, McLeod D, Fanning S, Kariyawasam V, Byth K. Complete Barrett’s excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy. 2011;43(12):1025–32. https://doi.org/10.1055/s-0030-1257049.

    Article  CAS  PubMed  Google Scholar 

  130. Desai M, Saligram S, Gupta N, Vennalaganti P, Bansal A, Choudhary A, Vennelaganti S, He J, Titi M, Maselli R, Qumseya B, Olyaee M, Waxman I, Repici A, Hassan C, Sharma P. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85(3):482–95e484. https://doi.org/10.1016/j.gie.2016.09.022.

    Article  PubMed  Google Scholar 

  131. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(10):1245–55. https://doi.org/10.1016/j.cgh.2013.03.039.

    Article  PubMed  Google Scholar 

  132. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–8. https://doi.org/10.1053/j.gastro.2011.04.061.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Cotton CC, Wolf WA, Overholt BF, Li N, Lightdale CJ, Wolfsen HC, Pasricha S, Wang KK, Shaheen NJ, Group AIMDT. Late recurrence of Barrett’s Esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology. 2017;153(3):681–8e682. https://doi.org/10.1053/j.gastro.2017.05.044.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Qumseya BJ, Wani S, Desai M, Qumseya A, Bain P, Sharma P, Wolfsen H. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(8):1086–95e1086. https://doi.org/10.1016/j.cgh.2016.04.001.

    Article  PubMed  Google Scholar 

  135. Das KK, Falk GW. Long-term outcomes for cryotherapy in Barrett’s esophagus with high-grade dysplasia: just cracking the ice. Gastrointest Endosc. 2017;86(4):633–5. https://doi.org/10.1016/j.gie.2017.03.1540.

    Article  PubMed  Google Scholar 

  136. Ramay FH, Cui Q, Greenwald BD. Outcomes after liquid nitrogen spray cryotherapy in Barrett’s esophagus-associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc. 2017;86(4):626–32. https://doi.org/10.1016/j.gie.2017.02.006.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, Di Pietro M, Ravi N, Visser M, Offerhaus GJ, Seldenrijk CA, Meijer SL, ten Kate FJ, Tijssen JG, Bergman JJ. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–17. https://doi.org/10.1001/jama.2014.2511.

    Article  CAS  PubMed  Google Scholar 

  138. Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJW, Seldenrijk CA, Offerhaus GJA, Visser M, Meijer SL, Mallant-Hent RC, Krishnadath KK, Pouw RE, Tijssen JGP, Shaheen NJ, Bergman J. Patients with Barrett’s esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to neoplasia. Gastroenterology. 2017;152(5):993–1001e1001. https://doi.org/10.1053/j.gastro.2016.12.008.

    Article  PubMed  Google Scholar 

  139. Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143(3):567–75. https://doi.org/10.1053/j.gastro.2012.05.010.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Phoa KN, Rosmolen WD, Weusten B, Bisschops R, Schoon EJ, Das S, Ragunath K, Fullarton G, DiPietro M, Ravi N, Tijssen JGP, Dijkgraaf MGW, Bergman J, investigators S. The cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial). Gastrointest Endosc. 2017;86(1):120–9e122. https://doi.org/10.1016/j.gie.2016.12.001.

    Article  PubMed  Google Scholar 

  141. Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Australian Cancer Study Clinical Follow-Up S, Watson DI. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79(2):242–256.e246. https://doi.org/10.1016/j.gie.2013.07.046.

    Article  PubMed  Google Scholar 

  142. Guthikonda A, Cotton CC, Madanick RD, Spacek MB, Moist SE, Ferrell K, Dellon ES, Shaheen NJ. Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2017;112(1):87–94. https://doi.org/10.1038/ajg.2016.451.

    Article  PubMed  Google Scholar 

  143. Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145(2):312–319.e311. https://doi.org/10.1053/j.gastro.2013.05.004.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc. 2000;52(2):197–203.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA, USA

    Adam Templeton, Andrew Kaz, Erik Snider & William M. Grady

  2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Andrew Kaz & William M. Grady

  3. Gastroenterology Section, VA Puget Sound Healthcare System, Seattle, WA, USA

    Andrew Kaz

Authors
  1. Adam Templeton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Kaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erik Snider
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William M. Grady
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William M. Grady .

Editor information

Editors and Affiliations

  1. Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA

    Nabil F. Saba

  2. Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA

    Bassel F. El-Rayes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Templeton, A., Kaz, A., Snider, E., Grady, W.M. (2020). Barrett’s Esophagus: Diagnosis and Management. In: Saba, N., El-Rayes, B. (eds) Esophageal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-29832-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-29832-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-29831-9

  • Online ISBN: 978-3-030-29832-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation